Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Solvency Ratios (Summary)

Vertex Pharmaceuticals Inc., solvency ratios (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Debt Ratios
Debt to equity
Debt to equity (including operating lease liability)
Debt to capital
Debt to capital (including operating lease liability)
Debt to assets
Debt to assets (including operating lease liability)
Financial leverage
Coverage Ratios
Interest coverage

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


Debt Ratios Including Operating Lease Liability
The debt to equity ratio remained stable at 0.04 from March to December 2021, then decreased slightly to 0.02 by December 2023. However, a rising trend emerged from March 2024, increasing to 0.11 by September 2025.
The debt to capital ratio followed a similar pattern, holding steady at 0.04 in early 2021, then declining to around 0.02 by late 2023. Afterward, it climbed notably from March 2024 onwards, reaching 0.10 in the third quarter of 2025.
The debt to assets ratio was consistently lower than the other debt metrics, starting at 0.03 in early 2021, decreasing to about 0.02 through most of 2023, and then increasing moderately after early 2024 to peak near 0.07 in late 2024 and 0.07 again in September 2025.
Financial Leverage
Financial leverage exhibited a gradual decline from 1.35 in March 2021 to approximately 1.28 by September 2022, followed by a slight increase fluctuating around 1.30 until late 2023. Beginning in early 2024, the ratio showed an upward trajectory, culminating at 1.44 by September 2025, indicating increasing use of debt relative to equity.
Interest Coverage Ratio
Interest coverage demonstrated strong performance with values consistently above 40 from 2021 through 2023, indicating robust ability to service interest expenses. This metric increased steadily, reaching over 111 by early 2024.
Notably, a sharp decline occurred in the first half of 2024, dropping to single digits and even turning negative (-11.94) in the third quarter, suggesting potential challenges in covering interest obligations during that period.
A dramatic recovery followed, with interest coverage soaring to 258.29 and 348.55 in the last two quarters of 2024 and 2025 respectively, indicating a substantial improvement in earnings relative to interest expenses.
Summary of Trends and Insights
Overall, the company maintained low leverage and strong interest coverage from 2021 through 2023. The stable and low debt ratios combined with modest financial leverage reflect a conservative capital structure during that period.
The period starting in early 2024 marks a notable transition. Debt ratios and leverage increased, indicating higher reliance on debt financing. Concurrently, the temporary sharp decline and subsequent recovery in interest coverage suggest a significant but short-lived challenge in meeting interest obligations that was effectively remedied.
The surge in interest coverage after mid-2024 points to an enhancement in operational earnings or reduced interest expenses, strengthening the company’s capacity to service debt despite increased leverage.

Debt Ratios


Coverage Ratios


Debt to Equity

Vertex Pharmaceuticals Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Shareholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The financial data for Vertex Pharmaceuticals Inc. reveals key trends in shareholders' equity over the quarterly periods from March 31, 2021, to September 30, 2025. No data is provided for total debt or the debt-to-equity ratio, limiting the analysis to equity trends only.

Shareholders' Equity Trend
There is a consistent upward trajectory in shareholders' equity from $8,980,254 thousand in March 2021 to a peak of $18,546,600 thousand by March 2024. This increase suggests sustained growth in the company’s net assets over this approximately three-year period.
Intermediate Fluctuations
While the overall trend is positive, there is a noticeable decline in equity in the mid-2024 period. Specifically, the equity decreases from $18,546,600 thousand in March 2024 to $14,774,700 thousand in June 2024, indicating a significant reduction. However, the equity recovers in subsequent quarters, reaching $17,318,800 thousand by September 2025.
Recent Stability
From December 2024 through September 2025, shareholders' equity shows relative stabilization, fluctuating modestly around $16,409,600 to $17,318,800 thousand. This suggests that any volatility experienced mid-2024 did not persist into the later quarters.
Implications
The growth in shareholders' equity suggests successful value creation for shareholders over the majority of the period analyzed. The sharp dip in mid-2024 warrants further investigation to understand potential causes such as one-time charges, restructuring, dividend payments, or other impacts. The absence of debt and debt-to-equity ratio data limits the ability to evaluate leverage and capital structure developments.

Debt to Equity (including Operating Lease Liability)

Vertex Pharmaceuticals Inc., debt to equity (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Long-term operating lease liabilities
Total debt (including operating lease liability)
 
Shareholders’ equity
Solvency Ratio
Debt to equity (including operating lease liability)1

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Shareholders’ equity
= ÷ =


The analysis of the provided financial data reveals notable trends in the company's capital structure over the examined quarters.

Total Debt (Including Operating Lease Liability)
The total debt remained relatively stable from the first quarter of 2021 through the first quarter of 2024, fluctuating around a range between approximately 348 million to 382 million US dollars. However, starting in the second quarter of 2024, there is a significant increase in total debt, with amounts rising sharply beyond 586 million and reaching over 1.8 billion US dollars by the third quarter of 2025. This marks a considerable escalation in the company's leverage during the latter periods.
Shareholders' Equity
Shareholders' equity demonstrated a steady and consistent increase throughout most of the period studied. Beginning at roughly 8.98 billion US dollars in the first quarter of 2021, equity expanded progressively until peaking near 18.55 billion by the first quarter of 2024. Notably, in the subsequent quarters of 2024 and into 2025, a slight decrease is observed, followed by a gradual recovery to approximately 17.3 billion US dollars by the third quarter of 2025.
Debt to Equity Ratio (Including Operating Lease Liability)
This ratio remained quite low and stable, between 0.02 and 0.04, from early 2021 up to the first quarter of 2024, reflecting a conservative capital structure with low reliance on debt relative to equity. From the second quarter of 2024 onwards, the ratio exhibits a sharp increase, reaching a high of 0.11 by the third quarter of 2025. This correlates with the surge in total debt and indicates a significant shift towards higher leverage in the company's financing approach during the latter period.

In summary, the financial data indicates that while shareholders' equity generally grew over the initial years maintaining a robust capitalization, the company markedly increased its debt levels starting in mid-2024. This strategic shift towards greater leverage is evident in the sharp rise of the debt-to-equity ratio, suggesting altered financial risk exposure and potential changes in financing strategy or investment needs during the recent quarters.


Debt to Capital

Vertex Pharmaceuticals Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Shareholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


The analysis of the available quarterly financial data reveals limited information due to the absence of values for total debt and debt to capital ratio. However, the data for total capital, measured in thousands of US dollars, provides insight into the company's capital trends over the observed periods.

Total Capital Trends

The total capital displays a consistent upward trajectory from March 31, 2021, through December 31, 2023. Beginning at approximately 8.98 billion US dollars in March 2021, it increased steadily to about 17.58 billion US dollars by December 2023. This growth suggests an expansion of the company's capital base, which could be indicative of increased equity, retained earnings, or other capital components.

However, following December 2023, the total capital values exhibit some irregularity. For instance, in June 2024, total capital decreases substantially to approximately 14.77 billion US dollars, after which it recovers and trends upwards again through the subsequent quarters, reaching around 17.32 billion US dollars by September 2025.

This fluctuation after December 2023 might reflect certain financial adjustments such as asset write-downs, capital restructuring, dividend distributions, share repurchases, or other corporate actions that temporarily reduce capital before stabilization and growth continue.

Absent Debt and Leverage Information

The absence of recorded values for total debt and the debt to capital ratio limits the ability to assess the company's leverage position, financial risk, and capital structure balance comprehensively. Without these metrics, conclusions regarding the company's reliance on debt financing or changes in its financial risk profile over the reported periods cannot be drawn.

Further analysis would require complete data on debt obligations and related ratios to provide a balanced view of financial stability and funding strategies.


Debt to Capital (including Operating Lease Liability)

Vertex Pharmaceuticals Inc., debt to capital (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Long-term operating lease liabilities
Total debt (including operating lease liability)
Shareholders’ equity
Total capital (including operating lease liability)
Solvency Ratio
Debt to capital (including operating lease liability)1

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =


The financial data demonstrates several notable patterns regarding the company's debt and capital structure over the analyzed periods.

Total Debt (Including Operating Lease Liability)
The total debt remained relatively stable from March 2021 through December 2023, fluctuating modestly around the $350 million to $380 million range. Beginning in the first quarter of 2024, there is a marked and significant increase in total debt, peaking around $1.58 billion by the third quarter of 2024 and maintaining elevated levels above $1.5 billion through mid to late 2025. This sharp rise suggests substantial new financing or obligations were undertaken starting in early 2024.
Total Capital (Including Operating Lease Liability)
Total capital exhibited a consistent upward trend from March 2021 until the end of 2023, growing steadily from approximately $9.3 billion to nearly $18 billion. However, this trend reverses abruptly in the first half of 2024, where a decline occurs, dropping to about $15.4 billion by mid-2024. Subsequent quarters show a recovery and renewed increase, reaching over $19 billion by late 2025. This volatility in capital may indicate changes in equity financing, asset base, or other capital components during 2024, before stabilizing and growing again.
Debt to Capital Ratio (Including Operating Lease Liability)
Throughout most of 2021 to 2023, the debt to capital ratio remained low and steady, around 0.02 to 0.04, reflecting a conservative leverage position. Starting in early 2024, the ratio rises sharply, climbing to approximately 0.09 to 0.10 by 2025, indicative of higher leverage. This increase aligns with the significant rise in total debt and the temporary decline in total capital, suggesting a strategic shift that increased reliance on debt financing relative to total capital.

In summary, the company maintained low and stable leverage through 2021–2023, characterized by steady growth in total capital and minimal changes in debt levels. However, beginning in early 2024, there is a substantial increase in total debt coupled with a temporary contraction in total capital, causing a notable rise in the debt to capital ratio. Such changes imply a potential shift in financial strategy, possibly to fund expansion, acquisitions, or other capital-intensive activities during this period. Following this, capital levels recover and continue to grow, while elevated leverage persists through 2025.


Debt to Assets

Vertex Pharmaceuticals Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The financial data presents a clear upward trajectory in total assets over the observed quarterly periods. Starting from approximately $12.1 billion in the first quarter of 2021, total assets increased consistently, reaching close to $24.9 billion by the third quarter of 2025. This steady growth suggests ongoing expansion or accumulation of resources over time.

Despite the detailed tracking of total assets, the absence of reported values for total debt and the corresponding debt-to-assets ratio limits the ability to assess leverage or financial risk directly. Without these metrics, it is challenging to comment on the capital structure changes or the company's reliance on debt financing.

The notable exception to the growth trend in total assets is observed in the middle of 2024, where there is a significant dip in assets from approximately $23.9 billion at the end of 2023 down to around $20.1 billion in mid-2024. This decline interrupts the otherwise upward trend. However, total assets subsequently rebound and continue their growth trajectory, indicating the dip could be due to a one-time event, asset revaluation, or another non-recurring factor.

Overall, the data reflects a robust growth pattern in asset accumulation over the time frame with one notable fluctuation. The absence of debt data prevents a thorough analysis of financial leverage or risk profile changes, hence conclusions related to solvency or debt management cannot be drawn from the provided information.


Debt to Assets (including Operating Lease Liability)

Vertex Pharmaceuticals Inc., debt to assets (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total debt
Long-term operating lease liabilities
Total debt (including operating lease liability)
 
Total assets
Solvency Ratio
Debt to assets (including operating lease liability)1

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =


The analysis of the financial trends over the observed periods reveals several key patterns in the company’s debt structure, asset base, and leverage ratios.

Total Debt (including operating lease liability)
The total debt remained relatively stable from early 2021 through the end of 2023, fluctuating around the range of approximately $350 million to $380 million. However, starting in the first quarter of 2024, there is a sharp and significant increase in total debt, reaching nearly $1.83 billion by the third quarter of 2025. This upward trend indicates a substantial rise in borrowing or lease liabilities over this later period, pointing to either increased leveraging or expanded financing activities.
Total Assets
Total assets displayed consistent growth from March 2021 to March 2024, rising steadily from about $12.1 billion to over $23.9 billion. Despite a slight dip in mid-2024, assets resumed an upward trajectory, ultimately reaching around $24.9 billion by September 2025. This pattern shows overall asset accumulation and expansion over the analyzed timeframe.
Debt to Assets Ratio (including operating lease liability)
The debt-to-assets ratio remained quite low and stable between 0.02 and 0.03 during the 2021 through early 2024 period, indicating a conservative leverage profile with debt representing only a small fraction of total assets. Starting from March 2024, the ratio increased notably to approximately 0.07 and stayed at that elevated level through the subsequent periods. This reflects the aforementioned increase in debt outpacing the growth in total assets, suggesting a shift towards higher leverage and potentially increased financial risk.

In summary, the company maintained a stable and low-leverage financial position through early 2024, supported by consistent growth in total assets. From 2024 onward, a marked increase in total debt altered the leverage structure, raising the debt-to-assets ratio and indicating a strategic or necessary shift toward greater indebtedness. This evolving financial profile warrants monitoring to assess the implications on solvency, risk, and financing costs going forward.


Financial Leverage

Vertex Pharmaceuticals Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Total assets
Shareholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The analysis of the financial data reveals several notable trends in the company's asset base, equity position, and financial leverage over the time periods observed.

Total Assets
Total assets demonstrated a consistent upward trajectory from March 31, 2021, to March 31, 2024, increasing from approximately $12.1 billion to $23.9 billion. This growth indicates sustained expansion in the company's asset holdings. However, a noticeable decline occurred in June 30, 2024, when total assets decreased significantly to about $20.1 billion, before recovering again to reach approximately $24.9 billion by September 30, 2025. Overall, the trend suggests steady growth with a temporary dip mid-period, followed by a recovery and further growth towards the end.
Shareholders’ Equity
Shareholders' equity increased steadily from around $8.98 billion at the start of the period to a peak of approximately $18.5 billion at the end of 2023. Similar to total assets, equity experienced a sharp decline from the peak to approximately $14.8 billion by June 30, 2024. Post this dip, shareholders’ equity showed consistent growth again, reaching about $17.3 billion by September 30, 2025. This pattern indicates that while the company strengthened its capital base significantly over the long term, it was subject to a substantial contraction mid-period but subsequently recovered.
Financial Leverage
Financial leverage ratios ranged from 1.28 to 1.44 during the entire period. Initially, the leverage ratio slightly decreased from 1.35 to approximately 1.28 by September 30, 2022, indicating a modest reduction in the use of debt relative to equity. Following this, financial leverage remained relatively stable near 1.3 until early 2024. Afterward, the leverage ratio rose steadily to 1.44 by September 30, 2025, suggesting an increase in debt relative to shareholders’ equity. The increase in leverage coincides with the periods when both assets and equity showed fluctuations, possibly reflecting a strategic adjustment in capital structure.

In summary, the company exhibited a strong growth in total assets and shareholders' equity over the majority of the analyzed period, interrupted by a notable mid-period contraction around mid-2024. Financial leverage displayed moderate volatility, with an overall trend toward increasing leverage in the later periods. This could indicate the company's evolving approach to balancing debt with equity financing amidst expansion and restructuring phases.


Interest Coverage

Vertex Pharmaceuticals Inc., interest coverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Net income (loss)
Add: Income tax expense
Add: Interest expense
Earnings before interest and tax (EBIT)
Solvency Ratio
Interest coverage1
Benchmarks
Interest Coverage, Competitors2
Amgen Inc.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Interest coverage = (EBITQ3 2025 + EBITQ2 2025 + EBITQ1 2025 + EBITQ4 2024) ÷ (Interest expenseQ3 2025 + Interest expenseQ2 2025 + Interest expenseQ1 2025 + Interest expenseQ4 2024)
= ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


Earnings before interest and tax (EBIT)
The EBIT values exhibit considerable volatility across the reported periods. Initially, the EBIT starts at a high level of 836,638 thousand US dollars in the first quarter of 2021, followed by a notable negative value in the subsequent quarter, indicating a significant loss. Subsequently, EBIT recovers strongly and maintains a generally positive trend through the end of 2023, with multiple quarters showing EBIT values exceeding 1 billion US dollars. However, in the first half of 2024, there is a sharp decline marked by a substantial negative EBIT value of -3,381,300 thousand US dollars, representing an exceptional downturn. Following this, EBIT rebounds and stabilizes in the later quarters, showing positive values generally above 700,000 thousand US dollars and reaching over 1.3 billion US dollars in early 2025.
Interest Expense
Interest expenses demonstrate a steady and consistent downward trend over the entire period. Starting from approximately 15,678 thousand US dollars in early 2021, interest expenses gradually decrease each quarter and reach a low of around 3,300 thousand US dollars by the first quarter of 2025. The continuous reduction in interest expense suggests a decline in debt levels or more favorable financing terms.
Interest Coverage Ratio
The interest coverage ratio reflects the company’s ability to meet interest obligations from EBIT. This ratio begins at a healthy level of approximately 56 in early 2021, although it dips in the second quarter of 2021 reflecting the negative EBIT during that period. Thereafter, the ratio displays a strong upward trend, consistently increasing to reach a peak of over 111 by the fourth quarter of 2023, indicating improving operating profitability relative to interest expense. A dramatic drop in interest coverage is observed in early 2024, coinciding with the substantial negative EBIT in the same period, reducing the ratio to a low of 6.14 and even turning negative in the third quarter of 2024 (-11.94). Following this disruptive period, the ratio recovers sharply to extremely high values above 250 by early 2025, reflecting a robust EBIT relative to much lower interest expenses.